Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | ABT-102 Tablets, 4 mg BID |
| 2 | ACTIVE_COMPARATOR | ABT-102 Tablets BID, escalating dose |
| 3 | ACTIVE_COMPARATOR | ABT-102 Tablets BID, escalating dose |
| 4 | PLACEBO_COMPARATOR | Placebo Tablets, BID |
| Name | Type | Description |
|---|---|---|
| ABT-102 | DRUG | BID tablets, 7 days of treatment |
| Placebo | DRUG | BID tablets, 7 days of treatment |
Inclusion Criteria: * Males and Females with a condition of general good health. * Must be willing to participate in all study-related procedures. Exclusion Criteria: * History of significant sensitivity to any drug. * Allergy to soy lecithin, soybeans, soybean oil, or other soybean derivatives. ...
ABT-102 is an investigational small molecule developed by Abbott Laboratories. It is a TRPV1 antagonist that has been studied in a Phase 1 clinical trial in healthy adult volunteers. No approved indication has been established for ABT-102.
ABT-102 targets TRPV1, also known as the transient receptor potential vanilloid 1 receptor. ABT-102 acts as a TRPV1 antagonist, meaning it is designed to block activity at this receptor. TRPV1 is a receptor involved in pain and sensory signaling.
ABT-102 is developed by Abbott Laboratories, which trades on the New York Stock Exchange under the ticker ABT. Abbott is the sponsor of the clinical program for this investigational compound.
ABT-102 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Only one clinical trial has been conducted, and that trial has been completed.
ABT-102 has been studied in one completed Phase 1 trial, NCT00854659, titled A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects. The trial enrolled 36 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.